BackAkero Therapeutics Overview

Akero Therapeutics Selling, General & Admin

See how AKRO's SG&A expenses trends over time vs similar companies.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$11.35M
19.87% YoY

As of Sep 30, 2025

Annual SG&A Expenses (TTM)

$43.02M
14.2% YoY

Trailing 12 months ending Sep 30, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Akero Therapeutics (AKRO) FAQ

Stockcircle tracks selling, general & admin for Akero Therapeutics (AKRO), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Akero Therapeutics's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main AKRO overview so you can move from this figure to the surrounding analysis quickly.